8-K: HOOKIPA Pharma Announces Positive Phase 2 Clinical Trial Results for HB-200 in Head and Neck Cancer

HOOKIPA Pharma reported encouraging Phase 2 clinical trial data for HB-200 in combination with pembrolizumab, showing promising results in patients with recurrent/metastatic HPV16+ head and neck cancer.

Summary

• HOOKIPA Pharma announced updated results from its Phase 2 clinical trial of HB-200 combined with pembrolizumab for patients with recurrent/metastatic HPV16+ head and neck cancer.
• The data, presented at the ASCO 2024 Annual Meeting, included 46 first-line patients and showed a favorable safety profile and promising clinical activity.
• In 35 evaluable patients, the combination therapy achieved a 37% confirmed objective response rate (ORR), an 11% complete response (CR) rate, and a 69% disease control rate (DCR).
• A subset of 17 patients with PD-L1 CPS of 20 or higher, representing the planned pivotal trial population, showed a 53% confirmed ORR, an 18% CR rate, and an 82% DCR.
• Preliminary progression-free survival (PFS) for the CPS 20 or higher subgroup was 16.3 months, compared to a historical PFS of 3.4 months for pembrolizumab alone.
• The preliminary overall survival (OS) rate was 88% at 9 months, with median OS not yet reached, and a median follow-up of 8.4 months.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results, with strong efficacy and a manageable safety profile. The company is also moving forward with a pivotal trial and has a path to potential accelerated approval. The sentiment is very positive from an investment perspective.

Positives

• The combination therapy showed a high objective response rate, particularly in the PD-L1 CPS 20 or higher subgroup.
• The complete response rate is encouraging, indicating a potential for significant tumor reduction.
• The disease control rate suggests that the treatment is effective in stabilizing the disease in a large proportion of patients.
• The preliminary progression-free survival is significantly longer than historical data for pembrolizumab alone.
• The overall survival rate is promising, with a high percentage of patients still alive at 9 months.
• The treatment was generally well-tolerated, with a low incidence of serious adverse events.

Negatives

• Grade 3 treatment-related adverse events were reported in 15% of patients.
• Serious treatment-related adverse events occurred in 4% of patients.
• Treatment-related adverse events led to discontinuation of HB-200 in 4% of patients.

Risks

• The data is from a Phase 2 trial and needs to be confirmed in larger Phase 3 trials.
• The long-term efficacy and safety of the combination therapy need to be further evaluated.
• The trial is ongoing, and the final results may differ from the preliminary data.
• The company is still in the early stages of development, and there are risks associated with drug development and regulatory approval.

Future Outlook

HOOKIPA plans to initiate a pivotal Phase 2/3 trial in the fourth quarter of 2024, targeting the patient population with PD-L1 CPS of 20 or higher. The company is also pursuing a path to potential accelerated approval with the FDA.

Management Comments

• Dr. Alan Ho, a trial investigator, stated he is encouraged by the potential of the immunotherapy combination as a targeted therapeutic option for HPV16+ head and neck cancer patients.
• Joern Aldag, CEO of HOOKIPA, stated that the company has a best-in-class asset with the HB-200 combination and has alignment on a clinical development strategy with the FDA.

Industry Context

The announcement is significant in the context of the immuno-oncology field, as it presents promising data for a novel combination therapy in a difficult-to-treat cancer. The results are being presented at a major oncology conference, ASCO, which highlights the importance of the findings. The company is positioning itself as a leader in arenaviral-based immunotherapies.

Comparison to Industry Standards

• The reported 16.3 months preliminary PFS for the CPS 20 or higher subgroup compares favorably to the 3.4 months PFS reported for pembrolizumab alone in the KEYNOTE-048 study.
• The 53% ORR in the CPS 20 or higher subgroup is a strong result compared to other treatments for recurrent/metastatic head and neck cancer.
• The 88% OS rate at 9 months is also encouraging, suggesting a potential survival benefit compared to standard of care.

Stakeholder Impact

• Shareholders will likely react positively to the promising clinical trial results.
• Patients with HPV16+ head and neck cancer may benefit from this new treatment option.
• Employees of HOOKIPA may be motivated by the positive progress of the company's lead candidate.
• The company's partners and collaborators may see increased value in the company's technology.

Next Steps

• The company plans to initiate a pivotal Phase 2/3 trial in the fourth quarter of 2024.
• The company will continue to develop its arenaviral-based immunotherapy platform.

Key Dates

Keywords

HB-200, pembrolizumab, HPV16+, head and neck cancer, immunotherapy, clinical trial, Phase 2, ASCO, objective response rate, complete response, progression-free survival, overall survival